Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for United Therapeutics Corporation (UTHR : NSDQ)

• Company Description    United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Number of Employees: 1,305

• Price / Volume Information    Yesterday's Closing Price: $448.91 Daily Weekly Monthly 20 Day Moving Average: 600,027 shares Shares Outstanding: 43.06 (millions) Market Capitalization: $19,328.54 (millions) Beta: 0.77 52 Week High: $479.50 52 Week Low: $266.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.03% -0.65% 12 Week 43.36% 37.42% Year To Date 27.23% 11.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SPRING ST - SILVER SPRING,MD 20910 USA ph: 301-608-9292 fax: 301-608-9291 ir@unither.com http://www.unither.com

• General Corporate Information    Officers Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James C. Edgemond - Chief Financial Officer and Treasurer Paul A. Mahon - Executive Vice President; General Counsel; and Cor Christopher Causey - Director Peer Information United Therapeutics Corporation (GSAC) United Therapeutics Corporation (CASI) United Therapeutics Corporation (ALCD.) United Therapeutics Corporation (OMNN) United Therapeutics Corporation (CGPI.) United Therapeutics Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 91307C102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 43.06 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.77 Market Capitalization: $19,328.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $6.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $26.85 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 3.74% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: 16.72 Trailing 12 Months: 17.01 PEG Ratio: 4.47 Price Ratios Price/Book: 2.93 Price/Cash Flow: 15.81 Price / Sales: 6.18 EPS Growth vs. Year Ago Period: 12.05% vs. Previous Quarter: 11.70% Sales Growth vs. Year Ago Period: 6.76% vs. Previous Quarter: 0.11% ROE 09/30/25 - 18.83 06/30/25 - 18.73 03/31/25 - 19.33 ROA 09/30/25 - 16.75 06/30/25 - 16.49 03/31/25 - 16.73 Current Ratio 09/30/25 - 6.40 06/30/25 - 7.26 03/31/25 - 5.46 Quick Ratio 09/30/25 - 6.07 06/30/25 - 6.94 03/31/25 - 5.23 Operating Margin 09/30/25 - 40.65 06/30/25 - 40.36 03/31/25 - 40.44 Net Margin 09/30/25 - 40.65 06/30/25 - 40.36 03/31/25 - 40.44 Pre-Tax Margin 09/30/25 - 53.27 06/30/25 - 52.54 03/31/25 - 52.23 Book Value 09/30/25 - 153.06 06/30/25 - 159.04 03/31/25 - 150.91 Inventory Turnover 09/30/25 - 2.13 06/30/25 - 2.12 03/31/25 - 2.17 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©